Trial Profile
An Open Label, Multicenter, randomized, phase III study to investigate the efficacy and safety of Bendamustine compared with Bendamustine + Obinutuzumab RO5072759 (GA101) in patients with Rituximab-refractory, indolent Non-Hodgkin's Lymphoma
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Obinutuzumab (Primary) ; Bendamustine
- Indications Follicular lymphoma; Non-Hodgkin's lymphoma
- Focus Registrational; Therapeutic Use
- Acronyms GADOLIN
- Sponsors Genentech
- 22 Nov 2020 This trial has been completed in Italy, according to European Clinical Trials Database record.
- 19 Nov 2020 Results comparing modelling approaches and assumptions related to the duration of treatment effect, presented at the 23rd Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
- 06 Nov 2019 Final results released in the 61st Annual Meeting and Exposition of the American Society of Hematology